News - Sandoz, Alimera Sciences

Filter

Current filters:

SandozAlimera Sciences

Popular Filters

1 to 25 of 62 results

Alimera resubmits NDA for Iluvien

Alimera resubmits NDA for Iluvien

27-03-2014

US ophthalmic pharma specialist Alimera Sciences has resubmitted its New Drug Application for Iluvien…

AlimeraAlimera SciencesIluvienOphthalmicsPharmaceuticalRegulationUSA

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

Sandoz to commercialize Taiwan Liposome’s antifungal

Sandoz to commercialize Taiwan Liposome’s antifungal

19-12-2013

Taipei-based biopharmaceutical company Taiwan Liposome Company has entered into a collaboration agreement…

Amphotericin BAntibiotics and Infectious diseasesAsia-PacificGenericsLicensingNovartisSandozTaiwan Liposome

Alimera says FDA advisory committee on Iluvien no longer necessary

Alimera says FDA advisory committee on Iluvien no longer necessary

19-12-2013

US ophthalmic pharma specialist Alimera Sciences has entered into labeling discussions with the US Food…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

Sandoz receives Danish approval for AirFluSal Forspiro inhaler

19-12-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has received Danish marketing authorization…

DenmarkPharmaceuticalRegulationRespiratory and PulmonarySandozVectura

Apricus expands Vitaros deal with Novartis unit

Apricus expands Vitaros deal with Novartis unit

16-12-2013

USA-based Apricus Biosciences has expanded its exclusive license agreement with Hexal AG, an affiliate…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalSandozVitaros

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

EC fines J&J and Novartis 16 million euros over fentanyl pay-for-delay deal

11-12-2013

The European Commission has imposed fines of 10.8 million euros ($14.8 million) on the US health care…

EuropefentanylFinancialJohnson & JohnsonNeurologicalNovartisPatentsPharmaceuticalSandoz

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

Sandoz in deal to market authorized generic of Shire’s Adderall XR in USA

03-12-2013

UK drugmaker Shire says that its subsidiary Shire US Inc has entered into an agreement to supply an authorized…

Adderall XRGenericsLicensingNeurologicalNorth AmericaNovartisSandozShire

UK’s NICE says yes to Alimera’s Iluvien

27-11-2013

In final guidance published this morning by UK drugs watch dog the National Institute for Health and…

Alimera SciencesDiabetesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

Sandoz appeals US court decision on AzaSite patent

Sandoz appeals US court decision on AzaSite patent

06-11-2013

US ophthalmic care specialist InSite Vision says that Sandoz Inc, the US generics unit of Swiss drug…

AzaSiteGenericsInSite VisionLegalNorth AmericaNovartisOphthalmicsPatentsSandoz

Novartis third quarter results driven by strong sales despite generic competition

Novartis third quarter results driven by strong sales despite generic competition

22-10-2013

Novartis has announced strong sales performance in its third quarter results, released today.

DiovanEuropeFinancialNorth AmericaNovartisPharmaceuticalSandozZometa

FDA calls for new trial before it can approve Alimera’s Iluvien

FDA calls for new trial before it can approve Alimera’s Iluvien

18-10-2013

USA-based ophthalmic biopharma specialist Alimera Sciences says that it has received a third Complete…

Alimera SciencesIluvienNorth AmericaOphthalmicsPharmaceuticalpSividaRegulation

Apricus ED drug gains national phase approval in Germany

09-10-2013

Germany's Federal Institute for Drugs and Medical Devices has granted national phase approval for USA-based…

Apricus BioscienceEuropeMen's HealthPharmaceuticalRegulationSandozVitaros

UK’s NICE recommends Iluvien for DME

02-10-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published final draft…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalpSividaRegulation

Avanir agrees settlement with Sandoz over Nuedexta

14-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into a settlement agreement with Swiss…

Avanir PharmaceuticalsGenericsLicensingNeurologicalNorth AmericaNuedextaPharmaceuticalSandoz

Proposal for a sole supply arrangement for fentanyl patches in New Zealand

08-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list a…

Asia-PacificfentanylFentanyl SandozNeurologicalNovartisPharmaceuticalPricingRegulationSandoz

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent

19-06-2013

USA-based Actavis (NYSE: ACT), itself predominantly a generic drug marketer, and Japan's Kissei Pharmaceutical…

ActavisGenericsHetero GroupMen's HealthNorth AmericaNovartisPatentsPharmaceuticalRapaflo CapsulesSandoz

NICE says "yes" to Alimera's Iluvien for treatment of diabetic macular edema

14-06-2013

In draft guidance published today (June 14) by UK drugs watch dog the National Institute for Health and…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

1 to 25 of 62 results

Company Spotlight

Fibrotech

Fibrotech

Back to top